“Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022” report gives comprehensive insight on clinical and non-clinical developments in the field of cancer immunotherapy. According to report, cancer immunotherapy has emerged as the new growth frontier for the pharmaceutical companies involved in the clinical research and development of cancer drugs and therapeutics. Currently there are more than 2000 cancer immunotherapies based drugs/therapies are in clinical pipeline. Majority of these are in preclinical, Phase-I and Phase-II trials. There are 14 cancer vaccine, 44 Cancer monoclonal antibodies, 3 cancer cell therapies and 61 cancer Immunomodulators are commercially available in the market.
Pharmaceutical companies are actively engaged in research and development of cancer immunotherapies because of large unmet medical necessities. Investigators are trying to come forth with innovative cancer immunotherapeutic products having high safety and efficacy profiles which are not offered by conventional therapeutics. Higher investments in research and development segment could significantly increase the drug discovery rates which will alleviate the medical condition of cancer patients. Simultaneously, technological advancements are being made due to which development of worthy candidates with high commercialization and pharmacological potential is expected to increase in coming years.
Investigators are trying to decipher underlying principle of cancer progression and proliferation. Different cancer indications have different requirements for developing effective therapeutics due to which identification of these factors have become important. This knowledge would be used for developing innovative cancer immunotherapies for various malignancies.
Cancer immunotherapeutics based on these discoveries would pave path for market introduction of highly effective therapeutics. Some progress has been made which could be noticed by observing plethora of cancer immunotherapeutics available for different cancer indications. Their clinical pipeline is also developing rapidly and various products are at different stages of clinical trials. They are expected to offer severe competition to presently available cancer therapeutics with modest pharmacological efficacy.
Cancer immunotherapies have been used for limited number of malignancies as compared to other drug categories. Mostly hematological malignancies like follicular lymphoma, chronic lymphocytic leukemia and diffuse large B cell non-Hodgkin’s lymphoma have remained the focal point. Other cancer indications like melanoma, NSCLC, prostate cancer and RCC have also got cancer immunotherapeutics.
Most like, cancer therapeutics in clinical trials would be able to present positive data that will allow them to easily enter in global market. Cancer incidences are escalating rapidly and cancer immuno therapeutics seems to play an important role in offering better medical care to patients. Some of them have received FDA’s accelerated approval and breakthrough therapy designation due to their superior pharmacological benefits. It is expected that similar progress would be shown by cancer immunotherapeutics under development for different malignancies.
“Global Cancer Immunotherapy Market and Clinical Trials Outlook 2022” report highlights:
Categorization of Cancer Immunotherapy
Market Aspects of Cancer Immunotherapy
Clinical Trials and Development Insight
Global Cancer Immunotherapy Pipeline Overview
Marketed Cancer Immunotherapy by Class
Global Cancer Immunotherapy Market Future Prospects
1. Immunotherapy: Mending Cancer Regimens
1.1 Preface to Cancer Immunotherapy
1.2 Evolution of Cancer Immunotherapy
2. Categorization of Cancer Immunotherapy
2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies
2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors
3. Fundamentals of Cancer Vaccines
3.1 Prologue of Cancer Vaccines
3.2 Cancer Vaccines in Immunotherapy
3.3 Commercial Aspects of Cancer Vaccines
4. New Era of Monoclonal Antibodies
4.1 Rudiments of Monoclonal Antibodies
4.2 Advents of Monoclonal Antibodies
4.3 Commercial Aspects of Monoclonal Antibodies
5. Trails of T-Cell Therapies
5.1 Adoptive Cell Transfer Technology
5.2 Strategies of Adoptive Cell Transfer
5.3 Commercial Aspects of Adoptive Cell Therapy
6. Aspects of Immune Checkpoint Inhibitors
6.1 Prelude to Immune Checkpoint Inhibitors
6.2 Implications of Immunecheck Point Inhibitors
6.3 Commercial Aspects of Immune Checkpoint Inhibitors
Table 4-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
Table 6-1: Illustration of Some Important Checkpoint Inhibitors
Table 9-1: Few Important Immunocytokines under Clinical Development
Table 9-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
Table 14-1: Few Commercially Important PD-1 Drugs
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.